Widespread RNA metabolism impairment in sporadic inclusion body myositis TDP43-proteinopathy

Neurobiology of Aging

Volumn 35, Issue 6, 2014, Pages 1491-1498

  Cortese, Andrea ^a,d   Plagnol, Vincent ^c   Brady, Stefen ^a   Simone, Roberto ^b   Lashley, Tammaryn ^a   Acevedo Arozena, Abraham ^e   De Silva, Rohan ^b   Greensmith, Linda ^a   Holton, Janice ^a   Hanna, Michael G ^a   Fisher, Elizabeth M C ^a   Fratta, Pietro ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

^d C MONDINO NATIONAL NEUROLOGICAL INSTITUTE   (Italy)

^e MEDICAL RESEARCH COUNCIL   (United Kingdom)

Author keywords

Amyotrophic lateral sclerosis; HnRNP; Inclusion body myositis; MAPT; RNA; TDP 43

Indexed keywords

RNA BINDING PROTEIN; TAR DNA BINDING PROTEIN; DNA BINDING PROTEIN; PROTEIN BINDING; PROTEIN TDP-43; RNA;

ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOPLASM; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MUSCLE BIOPSY; MYOSITIS; PRIORITY JOURNAL; PROTEIN LOCALIZATION; RNA METABOLISM; RNA SPLICING; RNA TRANSCRIPTION; SPORADIC INCLUSION BODY MYOSITIS; TDP 43 PROTEINOPATHY; TRANSCRIPTOMICS; AGED; AMYOTROPHIC LATERAL SCLEROSIS; FRONTOTEMPORAL DEMENTIA; GENETICS; INCLUSION BODY MYOSITIS; METABOLISM; MIDDLE AGED; PROTEIN TRANSPORT;

AGED; AMYOTROPHIC LATERAL SCLEROSIS; CYTOPLASM; DNA-BINDING PROTEINS; FRONTOTEMPORAL DEMENTIA; HUMANS; MIDDLE AGED; MYOSITIS, INCLUSION BODY; PROTEIN BINDING; PROTEIN TRANSPORT; RNA; RNA-BINDING PROTEINS; TDP-43 PROTEINOPATHIES;

EID: 84903372127     PISSN: 01974580     EISSN: 15581497     Source Type: Journal    
DOI: 10.1016/j.neurobiolaging.2013.12.029     Document Type: Article

References (40)

1. Amato A.A., Barohn R.J. Inclusion body myositis: old and new concepts. J.Neurol. Neurosurg. Psychiatr. 2009, 80:1186-1193.
2. Askanas V., Engel W.K., Nogalska A. Inclusion body myositis: a degenerative muscle disease associated with intra-muscle fiber multi-protein aggregates, proteasome inhibition, endoplasmic reticulum stress and decreased lysosomal degradation. Brain Pathol. 2009, 19:493-506.
3. Avendano-Vazquez S.E., Dhir A., Bembich S., Buratti E., Proudfoot N., Baralle F.E. Autoregulation of TDP-43 mRNA levels involves interplay between transcription, splicing, and alternative polyA site selection. Genes Development 2012, 26:1679-1684.
4. Benjamini Y., Hochberg Y. Controlling the False Discovery rate: a practical and powerful approach to multiple testing. Journal of the Royal statistical Society. Ser. B (Methodological) 1995, 57:289-300.
5. Bohan A., Peter J. Polymyositis and dermatomyositis (second of two parts). N.Engl. J. Med. 1975, 292:403-407.
6. Buratti E., Brindisi A., Giombi M., Tisminetzky S., Ayala Y.M., Baralle F.E. TDP-43 binds heterogeneous nuclear ribonucleoprotein A/B through its C-terminal tail: an important region for the inhibition of cystic fibrosis transmembrane conductance regulator exon 9 splicing. J.Biol. Chem. 2005, 280:37572-37584.
7. Cohen T.J., Lee V.M.Y., Trojanowski J.Q. TDP-43 functions and pathogenic mechanisms implicated in TDP-43 proteinopathies. Trends Mol. Med. 2011, 17:659-667.
8. D'Agostino C., Nogalska A., Engel W.K., Askanas V. In sporadic inclusion body myositis muscle fibres TDP-43-positive inclusions are less frequent and robust than p62 inclusions, and are not associated with paired helical filaments. Neuropathol. Appl. Neurobiol. 2011, 37:315-320.
9. D'Ambrogio A., Buratti E., Stuani C., Guarnaccia C., Romano M., Ayala Y.M., Baralle F.E. Functional mapping of the interaction between TDP-43 and hnRNP A2 invivo. Nucleic Acids Res. 2009, 37:4116-4126.
10. Engel W.K., Askanas V. Inclusion-body myositis: clinical, diagnostic, and pathologic aspects. Neurology 2006, 66:S20-S29.
11. Griggs R.C., Askanas V., DiMauro S., Engel A., Karpati G., Mendell J.R., Rowland L.P. Inclusion body myositis and myopathies. Ann. Neurol. 1995, 38:705-713.
12. Hernandez Lain A., Millecamps S., Dubourg O., Salachas F., Bruneteau G., Lacomblez L., LeGuern E., Seilhean D., Duyckaerts C., Meininger V., Mallet J., Pradat P.-F. Abnormal TDP-43 and FUS proteins in muscles of sporadic IBM: similarities in a TARDBP-linked ALS patient. J.Neurol. Neurosurg. Psychiatr. 2011, 82:1414-1416.
13. Huang D.W., Sherman B.T., Lempicki R.A. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat. Protoc. 2009, 4:44-57.
14. Irizarry R.A., Bolstad B.M., Collin F., Cope L.M., Hobbs B., Speed T.P. Summaries of Affymetrix GeneChip probe level data. Nucleic Acids Res. 2003, 31:e15.
15. Johnson J.O., Mandrioli J., Benatar M., Abramzon Y., Van Deerlin V.M., Trojanowski J.Q., Gibbs J.R., Brunetti M., Gronka S., Wuu J., Ding J., McCluskey L., Martinez-Lage M., Falcone D., Hernandez D.G., Arepalli S., Chong S., Schymick J.C., Rothstein J., Landi F., Wang Y.-D., Calvo A., Mora G., Sabatelli M., Monsurrò M.R., Battistini S., Salvi F., Spataro R., Sola P., Borghero G., Galassi G., Scholz S.W., Taylor J.P., Restagno G., Chiò A., Traynor B.J. Exome sequencing reveals VCP mutations as a cause of familial ALS. Neuron 2010, 68:857-864.
16. Kabashi E., Valdmanis P.N., Dion P., Spiegelman D., McConkey B.J., Vande Velde C., Bouchard J.-P., Lacomblez L., Pochigaeva K., Salachas F., Pradat P.-F., Camu W., Meininger V., Dupre N., Rouleau G.A. TARDBP mutations in individuals with sporadic and familial amyotrophic lateral sclerosis. Nat. Genet. 2008, 40:572-574.
17. Kawahara Y., Mieda-Sato A. TDP-43 promotes microRNA biogenesis as a component of the Drosha and Dicer complexes. Proc. Natl. Acad. Sci. U.S.A 2012, 109:3347-3352.
18. Kim H.J., Kim N.C., Wang Y.-D., Scarborough E.A., Moore J., Diaz Z., MacLea K.S., Freibaum B., Li S., Molliex A., Kanagaraj A.P., Carter R., Boylan K.B., Wojtas A.M., Rademakers R., Pinkus J.L., Greenberg S.A., Trojanowski J.Q., Traynor B.J., Smith B.N., Topp S., Gkazi A.-S., Miller J., Shaw C.E., Kottlors M., Kirschner J., Pestronk A., Li Y.R., Ford A.F., Gitler A.D., Benatar M., King O.D., Kimonis V.E., Ross E.D., Weihl C.C., Shorter J., Taylor J.P. Mutations in prion-like domains in hnRNPA2B1 and hnRNPA1 cause multisystem proteinopathy and ALS. Nature 2013, 495:467-473.
19. Küsters B., van Hoeve B.J.A., Schelhaas H.J., Ter Laak H., van Engelen B.G.M., Lammens M. TDP-43 accumulation is common in myopathies with rimmed vacuoles. Acta Neuropathol. 2009, 117:209-211.
20. Lagier-Tourenne C., Polymenidou M., Hutt K.R., Vu A.Q., Baughn M., Huelga S.C., Clutario K.M., Ling S.-C., Liang T.Y., Mazur C., Wancewicz E., Kim A.S., Watt A., Freier S., Hicks G.G., Donohue J.P., Shiue L., Bennett C.F., Ravits J., Cleveland D.W., Yeo G.W. Divergent roles of ALS-linked proteins FUS/TLS and TDP-43 intersect in processing long pre-mRNAs. Nat. Neurosci. 2012, 15:1488-1497.
21. Lee E.B., Lee V.M.-Y., Trojanowski J.Q. Gains or losses: molecular mechanisms of TDP43-mediated neurodegeneration. Nat. Rev. Neurosci. 2012, 13:38-50.
22. Leroy O., Wang J., Maurage C.-A., Parent M., Cooper T., Buée L., Sergeant N., Andreadis A., Caillet-Boudin M.-L. Brain-specific change in alternative splicing of Tau exon 6 in myotonic dystrophy type 1. Biochim. Biophys. Acta 2006, 1762:460-467.
23. Liquori C.L., Ricker K., Moseley M.L., Jacobsen J.F., Kress W., Naylor S.L., Day J.W., Ranum L.P. Myotonic dystrophy type 2 caused by a CCTG expansion in intron 1 of ZNF9. Science 2001, 293:864-867.
24. Mackenzie I.R., Rademakers R., Neumann M. TDP-43 and FUS in amyotrophic lateral sclerosis and frontotemporal dementia. Lancet Neurol. 2010, 9:995-1007.
25. Mirabella M., Alvarez R.B., Bilak M., Engel W.K., Askanas V. Difference in expression of phosphorylated tau epitopes between sporadic inclusion-body myositis and hereditary inclusion-body myopathies. J.Neuropathol. Exp. Neurol. 1996, 55:774-786.
26. Mishra M., Paunesku T., Woloschak G.E., Siddique T., Zhu L.J., Lin S., Greco K., Bigio E.H. Gene expression analysis of frontotemporal lobar degeneration of the motor neuron disease type with ubiquitinated inclusions. Acta Neuropathol. 2007, 114:81-94.
27. Nalbandian A., Donkervoort S., Dec E., Badadani M., Katheria V., Rana P., Nguyen C., Mukherjee J., Caiozzo V., Martin B., Watts G.D., Vesa J., Smith C., Kimonis V.E. The multiple faces of valosin-containing protein-associated diseases: inclusion body myopathy with Paget's disease of bone, frontotemporal dementia, and amyotrophic lateral sclerosis. J.Mol. Neurosci. 2011, 45:522-531.
28. Needham M., Mastaglia F.L. Inclusion body myositis: current pathogenetic concepts and diagnostic and therapeutic approaches. Lancet Neurol. 2007, 6:620-631.
29. Niblock M., Gallo J.-M. Tau alternative splicing in familial and sporadic tauopathies. Biochem. Soc. Trans. 2012, 40:677-680.
30. Oldfors A., Moslemi A.R., Jonasson L., Ohlsson M., Kollberg G., Lindberg C. Mitochondrial abnormalities in inclusion-body myositis. Neurology 2006, 66:S49-S55.
31. Oliv M., Janu A., Moreno D., Gmez J., Torrejn-Escribano B., Ferrer I. TAR DNA-Binding protein 43 accumulation in protein aggregate myopathies. J.Neuropathol. Exp. Neurol. 2009, 68:262-273.
32. Polymenidou M., Lagier-Tourenne C., Hutt K.R., Huelga S.C., Moran J., Liang T.Y., Ling S.-C., Sun E., Wancewicz E., Mazur C., Kordasiewicz H., Sedaghat Y., Donohue J.P., Shiue L., Bennett C.F., Yeo G.W., Cleveland D.W. Long pre-mRNA depletion and RNA missplicing contribute to neuronal vulnerability from loss of TDP-43. Nat. Neurosci. 2011, 14:459-468.
33. Rayavarapu S., Coley W., Nagaraju K. An update on pathogenic mechanisms of inflammatory myopathies. Curr. Opin. Rheumatol. 2011, 23:579-584.
34. Salajegheh M., Pinkus J.L., Taylor J.P., Amato A.A., Nazareno R., Baloh R.H., Greenberg S.A. Sarcoplasmic redistribution of nuclear TDP-43 in inclusion body myositis. Muscle Nerve 2009, 40:19-31.
35. Senderek J., Garvey S.M., Krieger M., Guergueltcheva V., Urtizberea A., Roos A., Elbracht M., Stendel C., Tournev I., Mihailova V., Feit H., Tramonte J., Hedera P., Crooks K., Bergmann C., Rudnik-Schneborn S., Zerres K., Lochmóller H., Seboun E., Weis J., Beckmann J.S., Hauser M.A., Jackson C.E. Autosomal-dominant distal myopathy associated with a recurrent missense mutation in the gene encoding the nuclear matrix protein, matrin 3. Am. J. Hum. Genet. 2009, 84:511-518.
36. Smyth G.K. Linear models and empirical bayes methods for assessing differential expression in microarray experiments. Stat. Appl. Genet. Mol. Biol. 2004, 3. Article3.
37. Sreedharan J., Blair I.P., Tripathi V.B., Hu X., Vance C., Rogelj B., Ackerley S., Durnall J.C., Williams K.L., Buratti E., Baralle F., de Belleroche J., Mitchell J.D., Leigh P.N., Al-Chalabi A., Miller C.C., Nicholson G., Shaw C.E. TDP-43 mutations in familial and sporadic amyotrophic lateral sclerosis. Science 2008, 319:1668-1672.
38. Subramanian A., Tamayo P., Mootha V.K., Mukherjee S., Ebert B.L., Gillette M.A., Paulovich A., Pomeroy S.L., Golub T.R., Lander E.S., Mesirov J.P. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. PNAS 2005, 102:15545-15550.
39. Tollervey J.R., Curk T., Rogelj B., Briese M., Cereda M., Kayikci M., Knig J., Hortobgyi T., Nishimura A.L., Zupunski V., Patani R., Chandran S., Rot G., Zupan B., Shaw C.E., Ule J. Characterizing the RNA targets and position-dependent splicing regulation by TDP-43. Nat. Neurosci. 2011, 14:452-458.
40. Weihl C.C., Temiz P., Miller S.E., Watts G., Smith C., Forman M., Hanson P.I., Kimonis V., Pestronk A. TDP-43 accumulation in inclusion body myopathy muscle suggests a common pathogenic mechanism with frontotemporal dementia. J.Neurol. Neurosurg. Psychiatr. 2008, 79:1186-1189.